Beactica is a TPD Company to Watch 2025
In a report published by the leading global business information provider Clarivate in October 2025, Beactica Therapeutic is highlighted as one of six emerging innovators changing the drug discovery and development paradigm by using targeted protein degradation (TPD) to develop precision interventions for 'undruggable' targets.
Learn More
Listen to our CEO on the BioBiz Buzz podcast
Listen to our CEO, Per Källblad, on the BioBiz Buzz podcast. In a conversation with host Mike Ward, he unpacks how the company’s Eclipsor™ platform synergises across allosteric modulation and targeted protein degradation, opening new possibilities for proteins once considered “undruggable.”
Learn More
"Beactica has a rich and unique history of creating impact and has always been dedicated to excellence and innovation. We use our passion for science combined with the exceptional skills, expertise and scientific knowledge of our team to discover and develop novel therapeutics and make a difference where it really matters."
- Per Källblad Ph.D. Chief Executive Officer
Learn More
Maximising impact with targeted protein degradation
With a clear vision and focus, we are leveraging targeted protein degradation to meticulously develop breakthrough solutions that specifically and effectively target disease-generating proteins.
Learn More
Offering compelling investment opportunities
With support from purposeful, mutually beneficial investments, we deliver value to patients and stakeholders. Our historic success in lead generation using our partner-validated drug development technology offers a secure foundation for the growth and advancement of our proprietary novel therapeutics to be progressed into the clinic.
Learn MoreStay Updated
Sign up for the Beactica newsletter to receive our latest news and updates